• Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable
    13 replies, posted
https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html
Man the satire just writes itself.
Is eating bankers a sustainable food production model?
Seize the meat of production
Maybe not, but I have a feel if that became a popular trend, curing patients would suddenly appear a lot more sustainable.
Goldman Sachs my fucking dick lmao
This really isn’t as shocking as the headline makes it out to be. If cures work effectively and also reduce the number of carriers in the future, the total number of patients will decline. Meaning less revenue from dispensing cures. Their solution to the problem wasn’t ‘make ineffective cures’. They actually recommended three solutions, and all of them have to do with diversification into new areas where other cures are needed: "Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually." "Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe." "Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets."
And here I thought this was going to be about the interesting discussions going on epidemiology/pharmacology these days, but no, it was just the usual cartoonishly evil shit. The interesting discussions revolve around drug resistance and the fact that vaccinations are causing/may cause virii to diversify, reducing their effectiveness in the long run, whilst at the same time humanity as a species is actually lowering its overall resistance to disease by sheltering and allowing to breed individuals with reduced immune systems who would have died without modern medicine. Not that any of the scientists involved in the debate are advocating that we should never have started, but they're more worried about trying to arrest/reduce this headlong plunge into mass outbreaks again, with some of them hoping that things like CRISPR might allow us to buff up our immune systems collectively at a genetic level etc.
Crazy conspiracy nuts will love this
I'm sure the market will fix this by creating more sick people!
Luckily for them, the market doesn't need to do anything, what with the growth of drug resistant diseases.
Or you could read the article and see that the Goldman Sachs analysts recommend diversifying into curing other diseases.
It was a joke, I agree with your assessment of the article.
this should shock and anger no one - i understand why he asked the question, and it makes sense from his point of view, this only adds to the argument that curing patients shouldnt necessarily be done in the pursuit for profit
Sorry, you need to Log In to post a reply to this thread.